21 May 2013
Keywords: rivaroxaban, cuts, vte, risk, record-1, trial, germany
Article | 17 December 2007
Germany's Bayer Schering Pharma, part of the Bayer group, says that data from a trial of the once-daily oral anticoagulent ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 December 2007
3 December 2007
20 May 2013
© 2013 thepharmaletter.com